The phase III KEYFORM-007 study (ClinicalTrials.gov identifier:
NCT05064059
) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...
N. Segal, Maria Passhak, F. Kose et al.· JCO Oncology Advances· 0 citations
BACKGROUND Small-cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis and marked transcriptional heterogeneity that may drive distinct therapeutic vulnerabilities. Clinical translation of molecular subtyping has been limited by restricted access to tumor biopsies, particularly at relapse. METHODS W...
Gavriel Fialkoff, N. Takahashi, Israa Sharkia et al.· Journal of Clinical Investig...· 0 citations
Overall survival was numerically longer after surgery than after SBRT, but the difference was not statistically significant, and SBRT may be a reasonable option for patients who cannot undergo surgery.
Nitsan Peled Oved, M. Wygoda, Adi Levy et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.